Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Share-based Compensation: 2018-2024

Historic Share-based Compensation for Silence Therapeutics (SLN) over the last 7 years, with Dec 2024 value amounting to $16.3 million.

  • Silence Therapeutics' Share-based Compensation fell 37.67% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.1 million, marking a year-over-year decrease of 14.46%. This contributed to the annual value of $16.3 million for FY2024, which is 0.20% up from last year.
  • According to the latest figures from FY2024, Silence Therapeutics' Share-based Compensation is $16.3 million, which was up 0.20% from $16.3 million recorded in FY2023.
  • In the past 5 years, Silence Therapeutics' Share-based Compensation registered a high of $16.3 million during FY2024, and its lowest value of $5.6 million during FY2020.
  • Its 3-year average for Share-based Compensation is $15.1 million, with a median of $16.3 million in 2023.
  • Data for Silence Therapeutics' Share-based Compensation shows a peak YoY surged of 656.88% (in 2020) over the last 5 years.
  • Silence Therapeutics' Share-based Compensation (Yearly) stood at $5.6 million in 2020, then spiked by 110.44% to $11.9 million in 2021, then climbed by 6.82% to $12.7 million in 2022, then increased by 28.28% to $16.3 million in 2023, then grew by 0.20% to $16.3 million in 2024.